Document is current

Article History

Received: 15 December 2025

Accepted: 20 March 2026

First Online: 15 April 2026

Declarations

:

: BS received travel support by AbbVie, Gilead, and Falk. HS has received research grants and support from Abbott Diagnostics and Amgen and honoraria from Amgen and Sanofi. PS, ES and SK are employed by Boehringer Ingelheim Pharma GmbH & Co.KG. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Alfasigma, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, MSD, Mirum, Novartis, Phenex, Pliant, ProQR Therapeutics, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, Madrigal, MSD and Mirum, as well as travel support from AbbVie, Falk, Gilead, Jannsen, Intercept and Ipsen. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as university employee) filed by the Medical University of Graz. TR received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking/writing honoraria from Abbvie, Echosens, Gilead, GSK, Intercept/Advanz Pharma, Pfizer, Roche, MSD, Siemens, W. L. Gore & Associates; consulting/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead, and Roche. PS received speaking/writing honoraria from Falk Pharma; consulting/advisory board fee from PharmaIN; and travel support from Falk Pharma. KBo, PK, HH, TS-N, VT, KBa, OP, BSH, GK, KS, KZ and KR declare no conflicts of interest.